FactSet: The Bargain Is Gone, Now the Rally Needs Proof

Read the headline "Barclays raises its target on FactSet" and you might picture an analyst warming to the stock. Read the actual note and it says the opposite: Barclays kept its Sell rating and nudged its price target up from $210 to $216, a token bump that still leaves the firm's fair value a full quarter below FactSet's trading price. That gap between what the headline sounds like and what it means is the whole current story for the stock.

FactSet (NYSE: FDS) sells the financial data, workstations, and analytics that portfolio managers and research desks build their days around. It is a subscription business with a stock that has spent the past year proving how far a good company and a good stock can drift apart.

The round trip

Pull up a 52-week chart and you see the trip the stock has taken. It cleared $377 around this time last year, then slid through the fall and winter toward a February low near $185, down roughly 30% at that point in 2026 as Barclays and others cut targets over "market data industry concerns" — pricing pressure and competition eating into a business whose growth had slowed. FactSet's revenue had grown just 5.4% in fiscal 2025, with organic subscription value up 5.7%. For a name that long traded at a premium multiple, a mid-single-digit growth rate felt like a broken promise, and the stock was punished through its fall.

Then the operating line stabilized and turned. Organic subscription value — the recurring revenue that will roll in over the next twelve months, the metric that carries this thesis — re-accelerated from 5.7% at the end of fiscal 2025 to 6.7% in the second quarter of fiscal 2026 and 7.1% by the third, ending May 31. Third-quarter revenue came in at $622.9 million, up 7% organically, with adjusted earnings of $4.53 per share ahead of estimates. Management framed AI as the driver, embedding it into products and cutting the tech workforce roughly 10% to pay for it, and cited steady subscription demand. The stock more than doubled off the February low, rallying about 45% in the last four months alone to sit near $302 today.

What the recovery has already priced in

Here is where the easy money ended. At the February low, FactSet traded around 11 times forward earnings — a genuine mispricing, where the valuation had reset far faster than the business had deteriorated, against a company still growing 7% and generating more than $700 million a year of free cash flow at a roughly 29% margin. That was a buy-the-fear setup, and it worked.

At roughly $302, the arithmetic flips. The stock now trades near 18 times forward earnings, roughly in line with — in some cases above — the sell-side's own targets. The average analyst target sits around $253, below the current price. This is the crux that separates good company from good stock: the market has already handed FactSet credit for the re-acceleration. Paying ~18x forward earnings for a business growing ~7% organically is not unreasonable, but it is no longer cheap, and it leaves no cushion for disappointment.

The honesty check is in the margins. FactSet's adjusted operating margin fell to 34.0% in the third quarter from 36.8% a year earlier — roughly 280 basis points of compression as the company invests in AI and pays for cuts. Full-year guidance of 34.0%–35.5% implies margins stay pinned at the compressed level rather than snapping back. The growth improvement has so far come with lower profitability, which is exactly the pattern that justifies skepticism about whether the AI push is durable revenue or a cost-heavy narrative.

The proof window

The next two to four quarters will tell the difference. FactSet reports its fourth-quarter fiscal 2026 results on September 30, followed by fiscal 2027 guidance — the first hard read on whether organic growth holds above 7% and whether margins stabilize, and the event most likely to move the stock off its current perch. A beat there, with ASV acceleration holding and margin pressure easing, would argue the ~18x multiple is deserved; growth that stalls back toward mid-single digits with margins staying thin would make the rally look ahead of the evidence.

The honest verdict is that the mispricing that made FactSet interesting in February has been captured. The stock is no longer cheap, its growth is modest, its margins are compressed, and the most prominent bear's target still sits well below the price. That does not make FactSet a sell — it is a quality business with a defensible recurring model and real cash flow. But from here the stock needs the AI story to show up as durable growth and rebounding margins, and that proof has not arrived yet. For a new buyer at $302, the risk is that you are paying full price for a recovery that already happened; the smarter posture is to watch the September 30 report decide it.

That is the lesson buried in the Barclays headline: a raised price target is not a raised rating, and a stock can fall a long way from its premium while the underlying business just modestly dips — and recover just as far before the operating numbers prove it should have.